Enveda, a biotechnology company using artificial intelligence to search for potential medicines in plants and microorganisms, has raised $311 million in Series E funding, pushing the company’s valuation to approximately $2 billion.
The financing round was led by Catalio Capital Management, with participation from Iconiq and other investors. The new investment represents a major increase in Enveda’s value, doubling the valuation the company reached roughly a year ago.
The funding comes as biotech companies increasingly explore whether AI can speed up one of the industry’s most difficult and expensive processes: finding promising drug candidates and determining which ones are worth taking into clinical development.
Enveda Looks to Nature for New Medicines
Enveda’s approach differs from traditional drug discovery, which often begins with molecules designed or synthesized in laboratories.
The company is searching for potential medicines in the natural world, including compounds produced by plants and microbes. Its technology combines biological research with AI-based analysis to identify substances that could have useful therapeutic properties.
The idea is rooted in a longstanding area of pharmaceutical research. Many existing medicines originated from compounds found in nature, but identifying and developing useful molecules from the enormous diversity of natural organisms can be a slow and difficult process.
Enveda’s goal is to use AI to make that search substantially faster.
A Startup Founded by a Recursion Veteran
Enveda was founded in 2019 by Viswa Colluru, who previously worked at Recursion Pharmaceuticals during the early stages of that company’s development.
Colluru launched Enveda with the aim of applying computational techniques to natural-product drug discovery, an area where the company believes conventional approaches have left significant potential unexplored.
The startup’s technology is intended to help researchers analyze complex biological data and identify compounds that might otherwise be overlooked.
AI Drug Candidates Are Reaching Human Trials
The new funding arrives at a time when enthusiasm around AI-driven drug discovery is growing, although the technology has yet to produce an FDA-approved medicine.
That distinction is important. AI is increasingly being used to identify and optimize potential drug candidates, but demonstrating that a medicine is safe and effective in humans remains a lengthy process.
Enveda is among the companies attempting to move AI-assisted discoveries beyond the laboratory and into clinical testing.
The company currently has multiple drug candidates being tested in human patients.
One program is focused on severe skin diseases, while another is aimed at helping people maintain weight loss after they stop taking GLP-1 medications.
The Next Test Is Clinical Success
The latest investment gives Enveda additional capital to advance its drug programs and continue developing its AI-based discovery platform.
For investors and the broader biotech industry, however, the company’s long-term value will ultimately depend on whether its experimental medicines can demonstrate meaningful benefits in clinical trials.
AI can potentially reduce the time researchers spend searching through enormous numbers of biological compounds, but a promising discovery still has to survive the difficult stages of drug development.
Enveda is betting that combining artificial intelligence with the chemical diversity found in nature can give researchers a new route to finding medicines.
With its valuation now at about $2 billion and several candidates already being tested in people, the company’s next phase will be closely tied to what those clinical trials reveal.
